Acute Lymphoblastic Leukemia

Can Treatments for Childhood ALL Alter the Gut Microbiome?

Can Treatments for Childhood ALL Alter the Gut Microbiome?

By

New research confirms that gut microbiome dysbiosis is present in survivors of childhood acute lymphoblastic leukemia.

The Biology and Genetics of Acute Leukemia: Two New Resources

The Biology and Genetics of Acute Leukemia: Two New Resources

Charles G. Mullighan, MBBS (Hons), MSc, MD, discusses the latest research out of St Jude at ASH 2018.

Pleural Effusions More Common Than Previously Thought in Dasatinib-Treated Leukemias

Pleural Effusions More Common Than Previously Thought in Dasatinib-Treated Leukemias

By

With newer treatments, alternatives to dasatinib exist, if needed.

Predictors of CAR-T-Associated Neurotoxicity in B-Cell Acute Lymphoblastic Leukemia

Predictors of CAR-T-Associated Neurotoxicity in B-Cell Acute Lymphoblastic Leukemia

By

High levels of CAR-T cell expansion in vivo and high pretreatment disease burden appeared to increase the likelihood that a neurotoxic event may occur following CAR-T administration.

Nelarabine May Improve Disease-Free Survival in Pediatric and Young Adult T-cell ALL

Nelarabine May Improve Disease-Free Survival in Pediatric and Young Adult T-cell ALL

By

The efficacy of nelarabine among newly diagnosed patients with T-cell ALL has not been fully explored.

FDA Expands Tisagenlecleucel Indication To Include Relapsed/Refractory B-cell Lymphomas

FDA Expands Tisagenlecleucel Indication To Include Relapsed/Refractory B-cell Lymphomas

By

The FDA based its approval on results of the single-arm phase 2 JULIET clinical trial.

Inotuzumab Ozogamicin May Improve Quality of Life in B-cell Acute Lymphocytic Leukemia

Inotuzumab Ozogamicin May Improve Quality of Life in B-cell Acute Lymphocytic Leukemia

By

Previous studies demonstrated that inotuzumab ozogamicin significantly improves clinical outcomes vs standard of care chemotherapy, but impact on QoL was unknown.

Acute lymphoblastic leukemia disease burden associated with safety and efficacy of CD19-CAR therapy

1. Patients with a higher disease burden of acute lymphoblastic leukemia (ALL) treated with CD19-specific chimeric antigen receptor (CAR) T cell therapy experienced greater incidences of cytotoxic release syndrome and neurotoxicity compared to low disease burden patients. 2. Patients with high disease burden had shorter overall survival times compared to low disease burden patients. Evidence []

Inotuzumab Ozogamicin Shows Similar Efficacy Among Older, Younger Patients With ALL

Inotuzumab Ozogamicin Shows Similar Efficacy Among Older, Younger Patients With ALL

By

Researchers evaluated the outcomes of older vs younger patients with R/R ALL treated with InO or investigators' choice of chemotherapy.

<i>TP53</i> Germline Mutations Associated With ALL Risk and Prognosis

TP53 Germline Mutations Associated With ALL Risk and Prognosis

By

Inherited TP53 variants may be crucial for acute lymphoblastic leukemia (ALL) leukemogenesis and response to treatment, according to a study published in the Journal of Clinical Oncology.1

Dasatinib Is Safe and Effective in Philadelphia Chromosome-positive Pediatric ALL

Dasatinib Is Safe and Effective in Philadelphia Chromosome-positive Pediatric ALL

By

Researchers assessed the efficacy of dasatinib — a TKI that is significantly more potent than imatinib and is active even in the setting of imatinib resistance — in this patient population.

Imatinib Increases Complete Response Rate, Decreases HSCT Allocation in Pediatric ALL

Imatinib Increases Complete Response Rate, Decreases HSCT Allocation in Pediatric ALL

By

Based on findings from previous studies (COG AALL0031 and EsPhALL 2004-2009), researchers are assessing the association of continuous imatinib plus chemotherapy with the reduced need for HSCT.

Acute Leukemia: Highlights from ASH 2017

Acute Leukemia: Highlights from ASH 2017

Elias Jabbour, MD, discusses the latest developments in the treatment of acute and chronic leukemia from the ASH 2017 meeting.

Inotuzumab Ozogamicin Plus Bosutinib May Be Safe, Effective for Relapsed/Refractory ALL and CML

Inotuzumab Ozogamicin Plus Bosutinib May Be Safe, Effective for Relapsed/Refractory ALL and CML

By

Eleven patients had a complete response: 10 had complete cytogenic remission, 8 were negative by flow cytometry, 6 had undetectable BCR-ABL. Three patients did not respond.

Unrelated HSCT, UCBT May Yield Similar Survival Outcomes in Acute Leukemia

Unrelated HSCT, UCBT May Yield Similar Survival Outcomes in Acute Leukemia

By

For a meta-analysis, researchers evaluated outcomes data from 9 studies consisting of 6762 patients with an acute leukemia to determine whether HSCT is superior to UCBT.

Minimal Residual Disease and Patient Genotype May Inform Relapse Risk Algorithms in ALL

Minimal Residual Disease and Patient Genotype May Inform Relapse Risk Algorithms in ALL

By

Previous studies demonstrated that MRD and genetic abnormalities are critical predictors of relapse in ALL, but current algorithms view MRD and genetics as independent variables when assessing risk.

Besponsa Approved for B-cell Acute Lymphoblastic Leukemia

Besponsa Approved for B-cell Acute Lymphoblastic Leukemia

By

The FDA granted approval to inotuzumab ozogamicin for the treatment of adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL).

CAR T Cell Therapy for Acute Lymphoblastic Leukemia: An Evolutionary Perspective

CAR T Cell Therapy for Acute Lymphoblastic Leukemia: An Evolutionary Perspective

By By

Enthusiasm for the CAR T cell approach may redirect rather than augment other possibly safer, more effective, evolutionarily informed approaches to cancer therapy.

Response-based Therapy Intensification Improves Survival in Adult ALL

Response-based Therapy Intensification Improves Survival in Adult ALL

By

Early response-based treatment intensification with allo-SCT improved OS among adult patients with early thymic precursor T cell ALL.

Quality of Life Among Pediatric Patients With Acute Lymphoblastic Leukemia

Quality of Life Among Pediatric Patients With Acute Lymphoblastic Leukemia

By

Long-term cure of ALL is achieved by 80% of children with the disease, but questions remain regarding how to balance morbidity and HRQoL related to treatment.

Despite Improvements, Survival Disparities Persist for Childhood Leukemia

Despite Improvements, Survival Disparities Persist for Childhood Leukemia

By

Leukemia remains the most common cancer type for children aged 14 years or younger, worldwide, representing a third of cases for children younger than 10 years.

Addition of Rituximab to Chemo Provides Survival Benefit in Acute Leukemia

Addition of Rituximab to Chemo Provides Survival Benefit in Acute Leukemia

By

The addition of rituximab to chemotherapy may benefit patients being treated for acute lymphoblastic leukemia (ALL).

Coping With Acute Lymphocytic Leukemia

Coping With Acute Lymphocytic Leukemia

This fact sheet provides patients with acute lymphocytic leukemia strategies for coping, treatment options, and more.

Inotuzumab Ozogamicin May Improve Survival for Patients With Acute Lymphoblastic Leukemia

Inotuzumab Ozogamicin May Improve Survival for Patients With Acute Lymphoblastic Leukemia

By

Patients with ALL treated with the monoclonal antibody inotuzumab ozogamicin were more likely to proceed to stem cell transplantation.

Ponatinib Induces Durable Responses in Patients With CML for at Least 4 Years

Ponatinib Induces Durable Responses in Patients With CML for at Least 4 Years

By

Ponatinib resulted in durable responses after 4 years in heavily pretreated patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.

Pre-labor Cesarean Delivery Linked With Higher Childhood Acute Leukemia Risk

Pre-labor Cesarean Delivery Linked With Higher Childhood Acute Leukemia Risk

By

Young children born by pre-labor cesarean delivery may be at an increased risk of childhood acute lymphoblastic leukemia (ALL).

Phase 3 Blinatumomab Study Meets Primary Survival Endpoint in Acute Leukemia

Phase 3 Blinatumomab Study Meets Primary Survival Endpoint in Acute Leukemia

By

Results of TOWER study evaluating blinatumomab in acute lymphoblastic leukemia (ALL) showed that the primary endpoint was met.

Pediatric-like Leukemia Treatment May Be Effective for Lymphoblastic Lymphoma

Pediatric-like Leukemia Treatment May Be Effective for Lymphoblastic Lymphoma

By

An intensive pediatric-like acute lymphoblastic leukemia (ALL) treatment protocol was associated with a good response rate.

Adding Rituximab Improves EFS in CD20-Positive, Ph-Negative Acute Leukemia

Adding Rituximab Improves EFS in CD20-Positive, Ph-Negative Acute Leukemia

By

Adding rituximab to the pediatric-inspired GRAALL protocol improved event-free survival in acute lymphoblastic leukemia.

Modular Domains Within Super Enhancer Drive T-ALL Drug Resistance

Modular Domains Within Super Enhancer Drive T-ALL Drug Resistance

By

The change in drug sensitivity by tumor cells resistant to Notch or BET inhibitors results from selective use of individual enhancers.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs